Navigation Links
Results From Investigator-Sponsored Trials Presented at SSIEM Conference
Date:9/1/2010

NOVATO, Calif., Sept. 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride) are being presented at the 2010 Annual Symposium of the Society for The Study of Inborn Errors of Metabolism (SSIEM), August 31st-September 3rd in Istanbul, Turkey. Investigators reported that PKU patients taking Kuvan showed improvements in brain functioning, mood and behaviors.

"While these investigator-sponsored studies were conducted in a small number of subjects, the results indicate benefits beyond lowering blood Phe levels, and we hope to document similar neurocognitive improvements in subjects with PKU in our recently initiated Phase 3b Kuvan outcomes study," said Dr. Hank Fuchs, Chief Medical Officer of BioMarin.  "If successful, the data will be submitted in support of a label amendment."

Highlights of Investigator-Sponsored Studies:Neurocognitive findings in individuals with Phenylketonuria and treatment with sapropterin dihydrochloride (BH4) (White, et al; Washington University, St. Louis): Baseline findings indicate that executive performance is worse for subjects with PKU as compared to non-PKU subjects across a range of executive functions such as inhibitory control, strategic processing and working memory. The results of this exploratory study suggest improvements in executive abilities following treatment with sapropterin.

Brain function in individuals with PKU treated with Kuvan: Evidence from functional magnetic resonance imaging (Christ, et al; University of Missouri-Columbia, USA): At baseline, irregularities in neural activation were observed in subjects with PKU in the prefrontal cortex (PFC) and other brain regions as compared to subjects without PKU. At four weeks, two early-treated PKU participants responded to Kuvan with
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
2. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
3. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
4. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
5. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
6. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
7. Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)
8. MedClean Technologies Announces Second Quarter Results
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015   Millar, Inc. , a ... announced the 2016 retirement of Craig Thummel , ... 12 years of service to the Company. The Company ... senior members of the Executive Management team as his ... Daugherty , currently Director of Sales and Marketing, as ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 /PRNewswire/ ... a late stage pharmaceutical company focused on the ... today announced the closing of its previously announced ... stock. The underwriters also exercised their over-allotment option ... of common stock. The net proceeds ...
(Date:6/30/2015)... June 24, 2015 ... addition of the "Global Array Instruments Market ... The global array instruments market to grow at ... 2014-2019 The global array instruments market can ... microarrays, and others including tissue microarrays and cell ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Roche announced today the opening of a new ... Nutley, N.J. The Roche Center of Excellence produces dosage ... and Phase 1 and 2 clinical studies. The 17,000 ... compounds into medicines for clinical trials. ...
... Sept. 30, 2011 The CyberKnife Coalition ... the CyberKnife Robotic Radiosurgery System® have now been enrolled ... track prostate cancer patients treated with stereotactic ... Radiosurgery (RPCR), tracks clinical and functional outcomes of men ...
Cached Medicine Technology:Roche Opens New Center of Excellence Facility 2First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2
(Date:6/30/2015)... ... 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of premium ... new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus on ... have come to know and respect for over eight years. , “I am thrilled ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... the community. , Eleven physicians from Allied’s Fullerton division volunteered to help provide ... annual Super Surgery Saturday, March 21, at St. Jude Medical Center. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice ... family of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Red Hot ... in a recent online poll at http://scoutology.com/novaburgerwars and was selected as “Best ... published in August 2015. , Red Hot & Blue President Randy McCann said, “Everyone ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion ... that fat transfer procedures had over breast implants when reconstructing breasts after a ... that “look and feel natural,” have increased sensation, and are less likely than ...
Breaking Medicine News(10 mins):Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3
... Wake Forest University Baptist Medical Center, US, have found ... children with cancer, and thus limits the side effects ... looked into the chemotherapy given to children suffering from ... type of childhood cancer were administered very limited dosage ...
... may be used to treat the problem of severe ... palsy. ,Children suffering from cerebral palsy and other ... have the control over the salivary reflex. This condition ... from being a constant problem for parents or people ...
... Medical School say that for people whose blood pressure do ... levels. ,In a healthy normal person blood pressure ... late night, or sleep disturbances may elevate the nighttime blood ... fact such higher levels of blood pressure at night may ...
... Researchers have identified a virus that targets and kills a ... virus (VSV) can successfully target and kill glioblastoma, which is ... a form of brain tumor that is resistant to modern ... Medicine had taken nine different DNA and RNA viruses through ...
... had invented a therapeutic vaccine Cytos002-NicQb that can cure//smokers ... quit smoking. ,Swiss researchers for the study, in ... had said that the vaccine for nicotine dependence had ... trials successfully. The first phase of the study had ...
... by Harvard School of Public Health suggests that obesity ... if already existing. ,Obesity had been conclusively associated ... and certain forms of cancer. This is for the ... asthma. ,In obese people lungs are under-expanded and ...
Cached Medicine News:
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: